Clinic effect of applying tirofiban on high and moderate-risk NSTE-ACS patients after a successful percutaneous coronary intervention treatment

Abstract

Objective To study how tirofiban (one kind of anti-platelet concentration drugs) reacts on non-ST-segment elevated acute coronary syndromes (NSTE-ACS) patients who were at moderate or high risk after percutaneous coronary intervention (PCI).Methods After operating PCI on the moderate or high risk NSTE-ACS patients in our hospital,the author divided these patients into observation group and control group.The control group was injected with normal saline,while the observation group was injected with tirofiban.After the injection,the safety and the effectiveness of the two groups were compared.Results After30 days of the operation,there was no remarkable difference of effectiveness endpoint between the two groups (P=0.40).There was no significant difference of composite endpoint after 7 days and 6 months as well.However,after 6 months the survival rate of the observation group was much higher than that of the control group (99.2％ vs 94.2％,log-rank P=0.03).Besides,the safety rates of the two groups had no significant difference.Conclusion After PCI,if the moderate or high risk NSTE-ACS patients are injected with tirofiban as the anti-platelet drug,the survival rate can be increased and the treatment is quite reliable. Key words: Acute coronary syndromes;  Percutaneous coronary intervention;  Anti-platelet concentration drugs